CD274 and neoplasm: Median duration of response by BICR with nivolumab plus chemotherapy was 8.4 months (95% CI 6.9–12.4) versus 5.7 months (95% CI 4.4–8.7) with chemotherapy in patients with tumor cell PD‐L1 expression ≥1% (Figure 1E).